论文部分内容阅读
目的观察莫邦(复方甘草酸单铵S)在防治肿瘤化疗引起的药物性肝损伤中的作用。方法将117例肿瘤化疗患者随机分为加复方甘草酸单铵S保肝治疗组59例,单纯化疗组58例,2周后复查肝功能,肝功能异常者,再行保肝治疗7d。结果同步保肝治疗组(A组)肝损伤发生率18.64%(11/59);单纯化疗组(B组)肝损伤发生率39.66%(23/58)。肝功能异常者经保肝治疗后A组7例显效,3例有效,有效率90.91%(10/11);B组15例显效,5例有效,有效率86.96%(20/23)。两组药物性肝损伤发生率差异有统计学意义(P<0.05)。结论复方甘草酸单铵S能预防、治疗肿瘤化疗引起的药物性肝损伤,保证了化疗周期按时、按量进行。
Objective To observe the role of mobon (compound glycyrrhizin monoammonium S) in the prevention and treatment of drug-induced liver injury induced by chemotherapy. Methods A total of 117 patients with tumor chemotherapy were randomly divided into treatment group with compound glycyrrhizin monoammonium S liver protection group of 59 cases, chemotherapy alone group of 58 cases, 2 weeks after the review of liver function, liver dysfunction, and then liver protection treatment for 7 days. Results The incidence of liver injury in group A was 18.64% (11/59). The incidence of liver injury in group B was 39.66% (23/58). In group B, 15 cases were markedly effective, 5 cases were effective, and the effective rate was 86.96% (20/23). The incidence of drug-induced liver injury in the two groups was significantly different (P <0.05). Conclusion Compound glycyrrhizin monoammonium S can prevent and treat drug-induced liver injury caused by chemotherapy of tumor, and ensure the chemotherapy cycle is on time and in quantity.